TEVAR 2016: Companies Push New Frontiers In Thoracic Aortic Interventions
Although thoracic endovascular aortic repair (TEVAR) is now routine for lesions like dissection of the descending aorta, the Big Three aortic endovascular companies are developing devices for the more technically challenging proximal and distal portions of the thoracic aorta while physicians refine TEVAR in the descending aorta. Insiders say endovascular techniques are overcoming limitations and physicians will soon be able to treat the entire aorta, from the aortic valve to the bifurcation.
You may also be interested in...
As endovascular aortic repair (EVAR) becomes a mainstream procedure, companies are racing to develop products that can treat patients with more challenging anatomy. As the space bubbles with ongoing trials and new-product launches, newer companies hope to make their mark in a space dominated by the established market leaders Medtronic PLC, Cook Medical Inc. and WL Gore & Associates.
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.